Overview

Tolerability of SLIT With LAIS® Mites Allergoid Tablets

Status:
Completed
Trial end date:
2017-02-28
Target enrollment:
Participant gender:
Summary
To expand knowledge on the application and tolerability of immunotherapy with LAIS® Mites allergoid tablets as well as knowledge on the alleviation of symptoms during sublingual therapy in special consideration of the chosen titration schedule in everyday practice.
Details
Lead Sponsor:
University Hospital of Cologne
Treatments:
Immunologic Factors